Overview
Shares of OneMedNet Corporation (NASDAQ:ONMD) surged 90% on Friday after the company disclosed that it is moving to the next phase of its commercial launch for a Real-World Data Platform powered by Palantir Foundry. The announcement said that customer evaluations are being converted into commercial subscriptions after the platform was shown with live feeds, subscription access, and AI-driven search capabilities at major tradeshows on November 10, 2025.
Commercial traction and revenue model
OneMedNet reported that it is signing multi-year subscription agreements that represent millions in incremental recurring revenue. The company said adoption is expanding across life sciences and AI health sectors as customers move from evaluation to paid subscriptions.
Platform scope and capabilities
The platform provides access to data from more than 2,130 healthcare sites and features multimodal datasets. OneMedNet described its iRWD network as offering continuously connected datasets with over 20 years of historical depth and access extending three years forward. The platform combines AI-driven search capabilities with real-time data feeds to support evidence generation.
According to the company, customer feedback since Fall 2025 emphasized the platform's analytical depth across integrated clinical and longitudinal datasets, improved cohort feasibility assessments, and faster onboarding of data partners. These attributes were cited as drivers for converting trials into subscription contracts.
"Customer feedback has reinforced the platform’s performance, speed, and depth of discovery," said Aaron Green, CEO & President. "We believe this traction validates our strategy of combining conversational AI-driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real-World evidence generation."
Business implications
OneMedNet emphasized that the commercial launch advances its recurring revenue model through multi-year subscription contracts, positioning the company to generate ongoing revenue streams tied to platform adoption.
Context limitations
The company statement focuses on the current commercial rollout, customer feedback since Fall 2025, and the conversion of evaluations to paid subscriptions. Details beyond the scope of those disclosures were not provided in the announcement.